Condition
Reflux Esophagitis (RE)
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07010107Phase 3RecruitingPrimary
A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
NCT06850480Phase 3RecruitingPrimary
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
NCT02153398Phase 3Completed
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
NCT01536080CompletedPrimary
Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life
Showing all 4 trials